SecBot SecBot
Biotech Drug Report Generated Nov 5, 2026

INVEGA HAFYERA

ALKS·Alkermes plc.
NEUTRAL
Drug Impact Rating3/10
Trial phase
Approved
Time to market
Already approved and marketed (FDA approved April 2023).
Why 3/10
INVEGA HAFYERA is an already-approved, marketed drug with no pending regulatory decision or pivotal readout. For Alkermes, it is a royalty revenue stream, not a development asset. No hard binary catalyst exists in the next ~12 months. The royalty term expires in May 2030, which is beyond the 12-month window.
Actionable Insight NEUTRAL

INVEGA HAFYERA has no upcoming binary catalyst for Alkermes because it is an already-approved, marketed drug generating royalties. The key date to watch is May 2030, when the royalty term expires and this revenue stream ends. For Alkermes, the more impactful near-term catalysts are its proprietary pipeline, including the ALKS 2680 orexin agonist program and LUMRYZ commercial execution.

Price Chart

Loading chart...

Executive Summary

INVEGA HAFYERA (paliperidone palmitate) is a long-acting injectable antipsychotic for schizophrenia, dosed once every six months. It was developed and is marketed by Janssen Pharmaceuticals (Johnson & Johnson), not by Alkermes. Alkermes plc (Nasdaq: ALKS) receives royalties on global sales of INVEGA HAFYERA through a licensing agreement that runs through May 2030. The drug was FDA-approved on April 26, 2023. For Alkermes, this is a passive royalty revenue stream, not a development-stage asset. In Q3 2026, Alkermes reported $26.4 million in combined royalty revenue from the INVEGA product family (XEPLION, INVEGA TRINZA/TREVICTA, and INVEGA HAFYERA/BYANNLI).

How It Works

INVEGA HAFYERA is an atypical antipsychotic that works by blocking dopamine and serotonin receptors in the brain. It is a long-acting injectable formulation of paliperidone that is administered by a healthcare professional into the gluteal muscle once every six months, making it the longest dosing interval available for schizophrenia treatment.

Trial Status

INVEGA HAFYERA was FDA-approved on April 26, 2023 based on a 12-month Phase 3 non-inferiority study showing 92.5% of patients were relapse-free at 12 months versus 95% for INVEGA TRINZA (the every-three-month formulation). The drug is commercially available and marketed by Janssen.

The Two-Sided Case

▲ Bull Case3
INVEGA HAFYERA provides a steady, predictable royalty revenue stream for Alkermes through May 2030, with no development cost or commercial risk to Alkermes.
The every-six-month dosing is the longest interval available for schizophrenia, which could drive adoption and market share growth, boosting Alkermes' royalty income.
The 2023 arbitration win with Janssen secured the royalty terms and also awarded back royalties, strengthening Alkermes' balance sheet.
▼ Bear Case4
INVEGA HAFYERA is not an Alkermes-owned asset; the company has no control over pricing, marketing, or commercial strategy. Royalty income depends entirely on Janssen's execution.
The royalty stream has a hard end date of May 2030, creating a finite revenue tail that investors must discount.
Combined royalty revenue from the INVEGA family was $26.4 million in Q3 2026, a relatively small portion of Alkermes' $480.1 million total quarterly revenue, limiting the drug's impact on the stock.
Competition from other long-acting antipsychotics (including generic paliperidone products like ERZOFRI from Luye Pharma approved July 2024) could pressure sales and royalties.

Upcoming Catalysts

  • No upcoming binary catalyst for INVEGA HAFYERA specifically. The royalty stream continues through May 2030 with no scheduled events.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Alkermes plc. 8-K ALKS ·Originating report

Sources · 9

Hover a chip for the title
1 drugs.com2 prnewswire.com3 fiercepharma.com4 docs.publicnow.com5 businesswire.com6 sec.gov7 accessdata.fda.gov8 invegasustennahcp.com9 sec.gov